MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.35 CHF | -1.47% |
|
+5.18% | -2.62% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 13.86M 15.31M | Sales 2025 * | 18.66M 20.6M | Capitalization | 113M 125M |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -65.14M | Net income 2025 * | -61M -67.35M | EV / Sales 2024 * | 8.14 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.05 x |
| P/E ratio 2024 * |
-2
x | P/E ratio 2025 * |
-1.83
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Molecular Partners AG
More recommendations
More press releases
| 1 day | +2.56% | ||
| 1 week | +1.19% | ||
| Current month | +3.34% | ||
| 1 month | -4.09% | ||
| 3 months | -16.05% | ||
| 6 months | -16.05% | ||
| Current year | -1.16% |
1 week
3.18
3.45
1 month
3.113.64
Current year
3.114.57
1 year
3.046.30
3 years
3.0428.90
5 years
3.0428.90
10 years
3.0438.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 04-11-22 | |
Patrick Amstutz
FOU | Founder | 49 | 04-11-22 |
Michael Pitzner
CMP | Compliance Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Burns
CHM | Chairman | 76 | 17-10-30 |
Steven Holtzman
BRD | Director/Board Member | 70 | 14-09-18 |
Vito Palombella
BRD | Director/Board Member | 61 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 3.35 | -1.47% | 9 105 |
| 24-05-03 | 3.4 | +2.56% | 43,540 |
| 24-05-02 | 3.315 | +0.76% | 25,475 |
| 24-04-30 | 3.29 | +3.30% | 7,037 |
| 24-04-29 | 3.185 | -5.21% | 7,114 |
Delayed Quote Swiss Exchange, May 03, 2024 at 11:30 am EDT
More quotes
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.4
CHF
Average target price
9.35
CHF
Spread / Average Target
+175.00%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.16% | 125M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +5.04% | 22.94B | |
| -12.15% | 22.34B | |
| -6.03% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +38.61% | 12.63B | |
| +313.59% | 8.49B |
- Stock Market
- Equities
- MOLN Stock